Clinical Trials Logo

Pinealoma clinical trials

View clinical trials related to Pinealoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03990597 Withdrawn - Glioma Clinical Trials

StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord

Start date: August 19, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects of a silicone topical wound dressing (StrataXRT) and to see how well it works in preventing radiation dermatitis (skin burns and side effects caused by radiation) in pediatric patients undergoing radiation therapy. StrataXRT may help prevent or decrease severe skin rash, pain, itching, skin peeling, and dry skin in pediatric patients undergoing radiation therapy to the brain or spinal cord.

NCT ID: NCT02194452 Withdrawn - Adult Glioblastoma Clinical Trials

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors

Start date: September 2013
Phase: N/A
Study type: Interventional

This pilot clinical trial studies gallium Ga 68-edotreotide (68Ga-DOTATOC) positron emission tomography (PET)/computed tomography (CT) in finding brain tumors in younger patients. Diagnostic procedures, such as gallium Ga 68-edotreotide PET/CT imaging, may help find and diagnose brain tumors.

NCT ID: NCT01182883 Withdrawn - Glioma Clinical Trials

A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors

Start date: July 28, 2010
Phase: Phase 1
Study type: Interventional

Background: - IMC-A12 is an experimental substance designed to inhibit a protein called Type I Insulin-Like Growth Factor Receptor (IGF-1R), which can be found on cancer cells and can promote cancer growth. Temsirolimus is a drug that the U.S. Food and Drug Administration has approved to treat advanced renal cell carcinoma in adults. Researchers do not know if the combination of IMC-A12 and temsirolimus will work in children, but want to determine whether these two drugs may be an effective treatment for recurrent tumors. Objectives: - To determine the safety and effectiveness of IMC-A12 and temsirolimus in treating children and adolescents with solid tumors. - To determine possible side effects of the combination of IMC-A12 and temsirolimus. Eligibility: - Children and adolescents between 12 months and 21 years of age who have solid tumors that have not responded to or have relapsed after standard treatment. Design: - Participants will be screened with a medical history, physical examination, and imaging studies. - Participants will receive IMC-A12 and temsirolimus in 28-day cycles of treatment. IMC-A12 will be given as an infusion over 1 hour, once a week, for 4 weeks. Temsirolimus will also be given after IMC-A12 over 30 minutes, once a week, for 4 weeks. - Participants may continue to receive IMC-A12 and temsirolimus for up to 2 years unless serious side effects develop or the treatment stops being effective. - Participants will have additional physical exams, blood and urine tests, and imaging studies regularly during each treatment cycle. - Participants will be followed at regular intervals after the end of the study to collect tumor response and progression data....